|Bid||69.13 x 1000|
|Ask||69.15 x 900|
|Day's range||68.85 - 69.95|
|52-week range||56.58 - 72.81|
|Beta (3Y monthly)||0.78|
|PE ratio (TTM)||20.86|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.
We'd be surprised if Henry Schein, Inc. (NASDAQ:HSIC) shareholders haven't noticed that an insider, Paul Brons...
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A federal appeals court on Thursday cleared the way for a landmark trial over the nation's opioid crisis, rejecting a bid by eight drug retailers and distributors to disqualify the judge, and a request by Ohio and other U.S. states to delay an Oct. 21 trial. The 6th U.S. Circuit Court of Appeals in Cincinnati said U.S. District Judge Dan Polster, who oversees nationwide opioid litigation, had not created an appearance of bias against the drug industry through his rulings, public statements, and efforts to encourage settlements.
Eight drug companies on Tuesday urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial in three weeks. The request came six days after U.S. District Judge Dan Polster in Cleveland refused to recuse himself and said he had done nothing to favor the state and local governments suing for damages, including by encouraging settlements. Polster oversees more than 2,300 of the roughly 2,600 lawsuits brought by state, local and tribal governments, hospitals and other entities seeking to hold the drug industry responsible for the toll of opioid abuse.
The U.S. judge overseeing nationwide opioid litigation on Thursday rejected a request by several big pharmacy chains and drug distributors to disqualify himself because he appeared to be biased against them and pressed too hard for a costly settlement. Companies that sought Polster's recusal included retailers CVS Health Corp, Rite Aid Corp, Walgreens Boots Alliance Inc and Walmart Inc, and distributors AmerisourceBergen Corp, Cardinal Health Inc, Henry Schein Inc and McKesson Corp.
In 1989 Stanley Bergman was appointed CEO of Henry Schein, Inc. (NASDAQ:HSIC). First, this article will compare CEO...
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Major drug wholesalers and retailers facing a massive lawsuit for allegedly fostering the nation's opioid crisis asked the judge hearing the case to recuse himself on Saturday. The companies argued in a court filing that U.S. District Judge Dan Polster, who is hearing the case in a federal court in Cleveland, Ohio, had made statements in court indicating that he was not impartial in the case and improperly pushed the companies to settle without going to trial. The companies said that Judge Polster had also made improper public comments about the case, including to reporters.
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day